Radionuclide therapy targeting FAP such as 177Lu-EB-FAPI is being investigated and the first-in-human trial for metastatic radioiodine-refractory thyroid cancer was conducted in 12 patients with objective response rate of 25% (62). Here, FAP is linked to thyroid cancer.